Mayo Clinic

Mayo Clinic is a nonprofit academic medical center headquartered in Rochester, Minnesota, with major campuses in Arizona and Florida. It traces its origins to 1864, has operated as a nonprofit since 1919, and has no stock ticker. It is best known for complex specialty care and research. It appears here not as an AI vendor but as a large nonprofit health system and AI adopter that has gone further than most hospitals into building models of its own. It does not sell a general-purpose AI model; its models reach other organizations through technology partners and spinout companies.

Its defining pattern is data-owner and model-builder. Mayo Clinic Platform aggregates de-identified patient records, and a November 2025 Mayo release put the archive at 26 petabytes of clinical information, including more than 3 billion laboratory tests, 1.6 billion clinical notes and more than 6 billion medical images. In January 2025 it and Cerebras Systems unveiled a genomic foundation model trained on public reference genomes plus exome data from 500 Mayo patients, aimed first at choosing rheumatoid arthritis treatments; it remains a research model. In July 2025 Mayo deployed an NVIDIA DGX SuperPOD built on Blackwell B200 systems and said the hardware cut pathology model work from four weeks to one. The first beneficiary was Atlas, a digital pathology foundation model built with the German company Aignostics and trained on more than 1.2 million whole-slide images.

The same data now anchors deals with drugmakers and technology companies. In February 2026 Merck & Co. signed a research collaboration that draws on Mayo Clinic Platform data to support its AI virtual cell work, starting with inflammatory bowel disease, atopic dermatitis and multiple sclerosis. No financial terms were disclosed, and the partners called it Mayo's first collaboration of that scale with a global drugmaker. In June 2026 Mayo and Microsoft announced a frontier AI model for clinical reasoning, built on Mayo's de-identified data. Mayo will own the model, it will be tested first inside Mayo's own clinical environment, and Microsoft plans to offer it to other providers through Azure Foundry, with no availability date announced.

Mayo also co-develops and buys specialist tools. In January 2025 it expanded ambient documentation from Abridge, running inside its Epic Systems health record, to about 2,000 clinicians, after co-developing a version for nurses with both companies. Earlier research reached patients through a spinout: an electrocardiogram (ECG) algorithm that flags low ejection fraction, a sign of a weakened heart, was built on Mayo research and more than 100,000 paired heart tests, and it received clearance from the U.S. Food and Drug Administration (FDA) in October 2023 as a product of Anumana.

The honest framing: Mayo's value rests on its clinicians, its reputation and above all its decades of longitudinal patient data, which is what partners are paying to reach. AI is the lever that turns that archive into models and deals. Much of the record is intention rather than measured result: the frontier model has no release date, the genomic model is a research artifact, and the four-weeks-to-one speedup is Mayo's own figure. The cleared ECG algorithm and the Abridge rollout are the parts already in routine care. Among catalog peers, Gilead procures specialists, Eli Lilly and Moderna build models to make drugs, and Merck & Co. and Novo Nordisk buy platforms; Mayo is the rare health system that owns the data those models need and is building a frontier model on it.